Compare KNTK & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNTK | BEAM |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 2017 | 2019 |
| Metric | KNTK | BEAM |
|---|---|---|
| Price | $47.98 | $32.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $48.58 | ★ $50.75 |
| AVG Volume (30 Days) | 1.1M | ★ 2.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.53% | N/A |
| EPS Growth | ★ 157.84 | 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $160,617,000.00 | $24,000.00 |
| Revenue This Year | $7.80 | N/A |
| Revenue Next Year | $13.93 | $33.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 8.23 | ★ 33.33 |
| 52 Week Low | $31.33 | $15.60 |
| 52 Week High | $51.51 | $38.26 |
| Indicator | KNTK | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 51.05 | 48.29 |
| Support Level | $44.64 | $23.83 |
| Resistance Level | $49.06 | $35.18 |
| Average True Range (ATR) | 1.41 | 2.84 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 42.97 | 21.32 |
Kinetik Holdings Inc is a midstream operator that provides comprehensive gathering, transportation, compression, processing and treating services. Its activities also include NGL stabilization and transportation, produced water gathering and disposal, and crude oil gathering, stabilization, storage, and transportation. The company operates in two reportable segments: i) The Midstream Logistics segment operates under three service offerings: 1) gas gathering and processing, 2) crude oil gathering, stabilization, and storage services, and 3) produced water gathering and disposal. ii) The Pipeline Transportation segment consists of two EMI Pipelines originating in the Permian Basin with various access points to the U.S. Gulf Coast, Kinetik NGL Pipelines, and Delaware Link Pipeline.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.